Maravai LifeSciences Holdings Inc.
05/29/2026 | Press release | Distributed by Public on 05/29/2026 14:19
Proxy Results (Form 8-K)
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 26, 2026, Maravai LifeSciences Holdings, Inc. (the "Company") held its 2026 Annual Meeting of Shareholders (the "Annual Meeting"). On March 27, 2026, the record date for the Annual Meeting, the Company had an aggregate of 258,180,170 shares of common stock outstanding, consisting of 147,496,090 shares of Class A common stock and 110,684,080 shares of Class B common stock (together, the "Common Stock"). The holders of a total of 236,082,968 shares of Common Stock were present at the Annual Meeting, either in person or by proxy, which constituted a quorum for the purpose of conducting business at the Annual Meeting.
Set forth below are the final voting results for each proposal submitted to a vote of the Company's shareholders at the Annual Meeting.
Proposal No. 1: Election of directors.
The Company's shareholders elected the following nominees for director to serve for three-year terms expiring at the Company's 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until his or her earlier death, resignation or removal.
| Nominee | Votes For | Votes Withheld | Broker Non-Votes | ||||||||
| Bernd Brust | 182,998,545.00 | 19,825,453.49 | 33,258,969.51 | ||||||||
| Gregory T. Lucier | 179,514,826.00 | 23,309,172.49 | 33,258,969.51 | ||||||||
| Luke Marker | 182,239,834.00 | 20,584,164.49 | 33,258,969.51 | ||||||||
Proposal No. 2: Proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.
The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified by the Company's shareholders.
| Votes For | Votes Against | Abstentions | ||||||
| 234,492,897.00 | 1,246,939.00 | 343,132.00 | ||||||
Proposal No. 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.
The Company's shareholders approved, on a non-binding and advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 200,054,156.49 | 2,457,403.00 | 312,439.00 | 33,258,969.51 | ||||||||
Maravai LifeSciences Holdings Inc. published this content on May 29, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 29, 2026 at 20:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]